Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) - Research analysts at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of Dynavax Technologies in a note issued to investors on Tuesday, January 14th. HC Wainwright analyst E. White anticipates that the biopharmaceutical company will earn $0.08 per share for the quarter. HC Wainwright has a "Buy" rating and a $31.00 price objective on the stock. The consensus estimate for Dynavax Technologies' current full-year earnings is $0.19 per share. HC Wainwright also issued estimates for Dynavax Technologies' Q3 2025 earnings at $0.12 EPS, FY2025 earnings at $0.35 EPS and FY2026 earnings at $0.45 EPS.
Separately, StockNews.com raised Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Tuesday.
Read Our Latest Stock Report on Dynavax Technologies
Dynavax Technologies Trading Down 0.4 %
DVAX stock traded down $0.06 during mid-day trading on Thursday, hitting $12.43. 332,756 shares of the company were exchanged, compared to its average volume of 1,882,654. The business has a fifty day simple moving average of $12.77 and a 200-day simple moving average of $11.66. The firm has a market capitalization of $1.63 billion, a P/E ratio of 95.51 and a beta of 1.34. Dynavax Technologies has a 12-month low of $9.74 and a 12-month high of $14.30. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.
Institutional Trading of Dynavax Technologies
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its position in Dynavax Technologies by 175.5% in the 3rd quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 1,685 shares during the last quarter. US Bancorp DE grew its stake in shares of Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 2,034 shares during the period. Capital Performance Advisors LLP acquired a new position in Dynavax Technologies during the third quarter worth about $45,000. Nisa Investment Advisors LLC increased its holdings in Dynavax Technologies by 44.6% in the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company's stock valued at $61,000 after buying an additional 1,679 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Dynavax Technologies during the 3rd quarter valued at approximately $89,000. Institutional investors and hedge funds own 96.96% of the company's stock.
About Dynavax Technologies
(
Get Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Articles
Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
